Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal
Shire is buying its way out of an ill-fated partnership with CTI BioPharma, which it inherited as part of the new pipeline acquired in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
